Bleeding
COVID-19 vaccine availability not tied to change in incidence of abnormal uterine bleeding
COVID-19 vaccination availability was not associated with changes in abnormal uterine bleeding incidence for women of reproductive age, researchers reported in the American Journal of Obstetrics and Gynecology.
Serotonin-based meds linked to lower risk of bleeding events 1 year post stroke
Treatment with selective serotonin/serotonin-norepinephrine reuptake inhibitors after ischemic stroke was associated with low risk of bleeding events at 1 year, according to a presenter at the International Stroke Conference.
One-third of gender-affirming testosterone users report breakthrough bleeding
One-third of transgender and gender-diverse individuals on testosterone will experience at least one breakthrough bleeding episode, even after their first year of use, researchers reported in the American Journal of Obstetrics and Gynecology.
Factor XI inhibitor for AF drastically reduces bleeding vs. rivaroxaban in phase 2 trial
PHILADELPHIA — In a phase 2b trial, abelacimab, a novel factor XI inhibitor, drastically reduced bleeding compared with rivaroxaban in patients with atrial fibrillation requiring stroke prevention.
In patients with subclinical AF, apixaban reduces stroke risk, raises bleeding risk
PHILADELPHIA — In patients with subclinical atrial fibrillation, apixaban lowered risk for stroke but increased risk for bleeding compared with aspirin, according to the results of the ARTESIA trial.
Triple drug-coated stent may reduce risk for stent thrombosis, target lesion failure
SAN FRANCISCO — The first-time application of a triple-drug, site-specific antithrombotic therapy on a stent platform was safe and effective for managing thrombotic and bleeding risk after PCI, data presented at TCT 2023 show.
Switch to ticagrelor monotherapy after 3-month DAPT safely reduces bleeding after PCI
SAN FRANCISCO — In a new meta-analysis, researchers reaffirmed safety and efficacy of ticagrelor monotherapy to reduce major bleeding after 3-month dual antiplatelet therapy among patients who underwent PCI for ACS.
Once-daily elagolix significantly reduces heavy menstrual bleeding for premenopausal women
Elagolix 150 mg once daily significantly reduced heavy menstrual bleeding from uterine leiomyomas among premenopausal women, according to trial results published in Obstetrics & Gynecology.
Transcatheter tricuspid valve replacement feasible with acceptable safety profile
SAN FRANCISCO — Transcatheter tricuspid valve replacement was feasible and had a lower-than-expected rate of safety events, according to an analysis of the first 150 patients in the TRISCEND II pivotal trial.
SWISS-APERO at 1 year: LAA closure outcomes similar for Amulet, Watchman devices
SAN FRANCISCO — One-year data from the SWISS-APERO study show similar clinical outcomes and rates of patent left atrial appendages for patients undergoing LAA closure with either the Amulet or Watchman FLX devices, a speaker reported.